Products & ServicesEvent: September 2, 2026
Absci's lead asset ABS-201 is currently in Phase 1/2a HEADLINE trial for pattern hair loss.
Published
Signal category
Products & Services
Quote
“Our lead asset, ABS-201, is currently in Phase 1/2a HEADLINE trial for pattern hair loss.”
— Absci team
Company
Absci
Unlocking differentiated biology with generative AI
- Industry
- Biotechnology Research
- Location
- Vancouver, US
- Company size
- 162 employees
Absci is a data-first AI drug creation company designing differentiated therapeutics using generative AI. Our Integrated Drug Creation platform powers cutting-edge de novo AI models and AI lead optimization models aimed at designing better biologics against difficult-to-drug targets.
Founded 2011